2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Serologic Tests, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, Research, Translational Research, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3957 Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy

Shayna Sarosiek, MD, Christopher Doughty, MD2, Andrew Branagan, MD, PhD3, Camille Edwards, MD4, Tarek Mouhieddine, MD5, Hannah Chory, NP6, Margaret Kobs, NP7, Nina Budano8, Julia Nguyen9, Alexandra usher, MD10, Courtney Boyajian11, Kirsten Meid, MPH12, Steven Treon, MD, PhD13, Jorge J Castillo, MD14
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Brigham & Women’s Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Approximately 25% of patients with an IgM paraprotein develop peripheral neuropathy (PN), with anti-myelin-associated glycoprotein (MAG) antibodies identified in half of cases, causing a demyelinating neuropathy characterized by sensory ataxia and distal limb weakness. Anti-MAG PN is a progressive disorder that impairs function and quality of life. Rituximab monotherapy has limited efficacy and is frequently associated with an IgM flare that can worsen PN. Bruton tyrosine kinase inhibitors (BTKi) decrease the risk of rituximab-associated IgM flare and produce profound reductions in serum IgM in WM.

 

Therefore, we completed a prospective, single-arm phase II study of acalabrutinib plus rituximab (NCT05065554) in patients with anti-MAG antibodies, an IgM monoclonal gammopathy of clinical significance (MGCS) or WM, and a predominantly sensory demyelinating PN. Eligible patients had a modified Rankin Scale score ≥1 with progressive symptoms or ≥2. Treatment consisted of continuous oral acalabrutinib (100 mg twice daily; 28-day cycles) with rituximab weekly in cycles 1 and 4. The primary endpoint was to evaluate hematologic response rate. The key secondary endpoint was to evaluate the proportion of patients that achieve improvement or stability in PN based on the Inflammatory Rasch-built Overall Disability Scale (I-RODS) patient-reported disability scale. Additional secondary neurologic endpoints included the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, MRC distal sum score, INCAT sensory sum score, fatigue severity score (FSS), 9-hole peg test, 10-meter walk test, visual analog scale (VAS) and a neuropathy-specific quality of life scale (IN-QOL).

 

Enrollment is now complete with 12 patients, with 6 females, with a median age of 69 years (range 54-86) enrolled. Median I-RODS at baseline was 40 (range 24-47; 48=no disability). All patients had an IgM paraprotein (11 kappa, 1 lambda) with median baseline IgM of 497 mg/dL (range 226-2137). Median anti-MAG antibody titer was >70,000 IU/L (range 67,129->70,000). Three patients had WM (range of marrow involvement, 5-50%) and 9 had MGCS (7 with no detectable disease on bone marrow immunohistochemistry). No patients had adenopathy or splenomegaly on baseline scans. Seven patients had a MYD88MUT and none had a CXCR4MUT (0/10). Seven patients had prior treatment for anti-MAG PN (6 with rituximab and 5 with IVIG).  

 

Two patients were unevaluable for response: 1 patient removed from the trial after 28 days due to grade 3 elevation in ALT and one patient stopped therapy during cycle 1 due to personal preference.

 

For the ten evaluable patients median time on treatment was 37 months (range 22-46). Nine patients had an elevated IgM at baseline and overall response rate in those patients was 100% (1 CR, 4 VGPR, 3 PR, 1 MR). One patient had a normal serum IgM (292 mg/dL) at baseline and therefore IgM response was not evaluated per IWWM-11 criteria, but this patient’s IgM decreased to 167 mg/dL and M-spike decreased from 0.45 to 0.23 g/dL indicating a hematologic response. Median I-RODS score remained stable or improved in 6 of 10 patients. Eight of ten patients had an improvement in anti-MAG titer to a median of 52,595 IU/L (range 25,600-102,000). At least 50% of patients had stability or improvement in each neurologic outcome, including patient-reported outcomes [VAS (6/10), FSS (8/10)] and provider assessed outcomes [9-hole peg (7/10) and 10m walk (7/10), MRC distal sum score (8/10), INCAT ISS (9/10), INCAT disability (9/10)]. Five patients had improvement in EMG from baseline, four were stable, and one was worse (this patient withdrew from study treatment at 27 months due to worsening PN). There were four Grade 3 (no Grade 4) adverse events, two syncopal events unrelated to treatment, 1 rituximab infusion reaction, and 1 elevation in liver function related to treatment.


Anti-MAG PN is a persistently progressive disease. This study demonstrates the potential for achieving stability or improvement in anti-MAG PN. Both hematologic and neurologic responses were observed in this first prospective study evaluating a BTKi with rituximab in patients with IgM-related anti-MAG PN. All patients achieved a hematologic response. Eight patients had improvement in the anti-MAG titer. All neurologic parameters showed improvement or stability in at least half of patients by provider assessed and patient reported outcomes.  Further studies evaluating this therapy are warranted.

Shayna Sarosiek, MD: ADC Therapeutics - Research Funding; BeOne - Research Funding; Sobi - Research Funding; AstraZeneca - Research Funding; BeOne - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony)